About this guidance

SDCEP's Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw guidance, and accompanying Guidance in Brief,  was published in 2017. Following a scheduled review (completed March 2024), the 2017 edition of the guidance remains essentially unchanged and extant. A MRONJ guidance supplement providing updated information on incidence and drugs associated with MRONJ is available on the SDCEP website.

The information in this site is drawn mainly from the Guidance in Brief, with supplementary material from the full guidance where necessary.

For a full appreciation of the recommendations and further advice on following them, refer to the full guidance.

Both the full guidance and the Guidance in Brief are available to download from the SDCEP website.

The guidance is primarily directed at dentists in primary care dental practice, including the general dental service and public dental service, and is also of relevance to the secondary care dental service, those involved in dental education and undergraduate trainees.

Prescribers and dispensers of these drugs, as well as patients and their carers, where appropriate, may also find the information in this guidance of relevance.